Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma

Pharmaceutical Biology

Volumn 50, Issue 1, 2012, Pages 25-29

  Opoku Ansah, John ^a   Ibarra Rivera, Tannya R ^b,d   Pirrung, Michael C ^b   Bachmann, André S ^a,c  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d Department of Analytical Chemistry   (Mexico)

Author keywords

Anticancer activity; Bortezomib; Glidobactin A; Multiple myeloma; Natural products; Neuroblastoma; Pediatric cancer; Plant pathogen Pseudomonas syringae pv. syringae; Synthetic analogues; Syrbactins

Indexed keywords

BORTEZOMIB; CASPASE; CHYMOTRYPSIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PROTEASOME INHIBITOR; SYRINGOLIN A; SYRINGOLIN B; TIR 203; TRYPSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NEUROBLASTOMA; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE MYELOMA; NEUROBLASTOMA; PEPTIDES, CYCLIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UREA;

BACTERIA (MICROORGANISMS); PHASEOLUS VULGARIS; PSEUDOMONAS SYRINGAE PV. SYRINGAE; PUNCTUM BLANDIANUM;

EID: 84555191774     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2011.626784     Document Type: Article

References (25)

1. Adams J. (2004). Te proteasome: A suitable antineoplastic target. Nat Rev Cancer, 4, 349-360.
2. Archer CR, Koomoa DL, Mitsunaga EM, Clerc J, Shimizu M, Kaiser M, Schellenberg B, Dudler R, Bachmann AS. (2010). Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma. Biochem Pharmacol, 80, 170-178.
3. Bachmann AS. (2008). Proteasome inhibitors in pediatric cancer treatment. Hawaii Med J, 67, 247-249.
4. Clerc J, Florea BI, Kraus M, Groll M, Huber R, Bachmann AS, Dudler R, Driessen C, Overkleeft HS, Kaiser M. (2009a). Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem, 10, 2638-2643.
5. Clerc J, Groll M, Illich DJ, Bachmann AS, Huber R, Schellenberg B, Dudler R, Kaiser M. (2009b). Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc Natl Acad Sci USA, 106, 6507-6512.
6. Clerc J, Schellenberg B, Groll M, Bachmann AS, Huber R, Dudler R, Kaiser M. (2010). Convergent synthesis and biological evaluation of syringolin A and derivatives as eukaryotic 20S proteasome inhibitors. Eur J Org Chem, 21, 3991-4003.
7. Clerc J, Li N, Krahn D, Groll M, Bachmann AS, Florea BI, Overkleeft HS, Kaiser M. (2011). Te natural product hybrid of syringolin A and glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chem Commun (Camb), 47, 385-387.
8. Coleman CS, Rocetes JP, Park DJ, Wallick CJ, Warn-Cramer BJ, Michel K, Dudler R, Bachmann AS. (2006). Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Cell Prolif, 39, 599-609. (Pubitemid 44760209)
9. Dai C, Stephenson CR. (2010). Total synthesis of syringolin A. Org Lett, 12, 3453-3455.
10. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. (2003). Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and-resistant MM cells. Exp Hematol, 31, 271-282. (Pubitemid 36407603)
11. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, Dudler R. (2008). A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature, 452, 755-758. (Pubitemid 351521080)
12. Hirano SS, Upper CD. (2000). Bacteria in the leaf ecosystem with emphasis on Pseudomonas syringae-a pathogen, ice nucleus, and epiphyte. Microbiol Mol Biol Rev, 64, 624-653.
13. Ibarra-Rivera TR, Opoku-Ansah J, Ambadi S, Bachmann AS, Pirrung MC. (2011). Syntheses and cytotoxicity of syringolin B-based proteasome inhibitors. Tetrahedron. (In Press).
14. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Schefer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. (2008). Molecular basis of bortezomib resistance: Proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 112, 2489-2499.
15. Oka M, Nishiyama Y, Ohta S, Kamei H, Konishi M, Miyaki T, Oki T, Kawaguchi H. (1988a). Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity. J Antibiot, 41, 1331-1337. (Pubitemid 18259415)
16. Oka M, Numata K, Nishiyama Y, Kamei H, Konishi M, Oki T, Kawaguchi H. (1988b). Chemical modifcation of the antitumor antibiotic glidobactin. J Antibiot, 41, 1812-1822. (Pubitemid 19010349)
17. Oka M, Ohkuma H, Kamei H, Konishi M, Oki T, Kawaguchi H. (1988c). Glidobactins D, E, F, G and H; minor components of the antitumor antibiotic glidobactin. J Antibiot, 41, 1906-1909. (Pubitemid 19010360)
18. Oka M, Yaginuma K, Numata K, Konishi M, Oki T, Kawaguchi H. (1988d). Glidobactins A, B and C, new antitumor antibiotics. II. Structure elucidation. J Antibiot, 41, 1338-1350. (Pubitemid 18259416)
19. Orlowski RZ, Kuhn DJ. (2008). Proteasome inhibitors in cancer therapy: Lessons from the frst decade. Clin Cancer Res, 14, 1649-1657. (Pubitemid 351469448)
20. Pirrung MC, Biswas G, Ibarra-Rivera TR. (2010). Total synthesis of syringolin A and B. Org Lett, 12, 2402-2405.
21. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. (2010). Bortezomib-resistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 24, 1506-1512.
22. Shoji J, Hinoo H, Kato T, Hattori T, Hirooka K, Tawara K, Shiratori O, Terui Y. (1990). Isolation of cepafungins I, II and III from Pseudomonas species. J Antibiot, 43, 783-787. (Pubitemid 20239819)
23. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. (2005). Te p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA, 102, 731-736. (Pubitemid 40282734)
24. Terui Y, Nishikawa J, Hinoo H, Kato T, Shoji J. (1990). Structures of cepafungins I, II and III. J Antibiot, 43, 788-795. (Pubitemid 20239820)
25. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. (2003). Te proteasome as a target for cancer therapy. Clin Cancer Res, 9, 6316-6325.